Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by NextPoint Therapeutics

NextPoint Therapeutics Announces Upcoming Poster Presentation on a B7-H7 Directed T Cell Engager Therapy at SITC2024
From NextPoint Therapeutics
Via Business Wire
NextPoint Therapeutics Announces First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors
From NextPoint Therapeutics
Via Business Wire
NextPoint Therapeutics Chief Executive Officer Ivan Cheung Named to the 2024 TIME100 Health List
From NextPoint Therapeutics
Via Business Wire
NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
From NextPoint Therapeutics
Via Business Wire
NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
From NextPoint Therapeutics
Via Business Wire
NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer
From NextPoint Therapeutics
Via Business Wire
NextPoint Therapeutics Appoints Tatiana Novobrantseva, PhD, as Chief Scientific Officer
From NextPoint Therapeutics
Via Business Wire
NextPoint Therapeutics Announces IND Clearance from the FDA to Advance NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
From NextPoint Therapeutics
Via Business Wire
NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267, a Novel Therapeutic Targeting KIR3DL3 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
From NextPoint Therapeutics
Via Business Wire
Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors
From NextPoint Therapeutics
Via Business Wire
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer
From NextPoint Therapeutics
Via Business Wire
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs
From NextPoint Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.